Evidence map›Paper›PMID 26657199›Full record

Trial reportBlood cancer journal2015

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.

F Ravandi, A Pigneux, D J DeAngelo, E Raffoux, J Delaunay, X Thomas, T Kadia, H Kantarjian, J Scheuenpflug, C Zhao and 2 more

Abstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.European journal of drug metabolism and pharmacokinetics · 2018
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

F RavandiDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
A PigneuxService des Maladies du Sang, Centre François Magendie, Hôpital du Haut-Lévèque, Pessac, France.
D J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
E RaffouxDepartment of Adult Hematology, Hôpital Saint Louis, Paris, France.
J DelaunayDepartment of Hematology, Hôpital Hotel Dieu, Nantes, France.
X ThomasDepartment of Hematology, Hôpital Edouard Herriot, Lyon, France.
T KadiaDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H KantarjianDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J ScheuenpflugClinical Biomarkers, Merck KGaA, Darmstadt, Germany.
C ZhaoClinical Oncology, Early Development, EMD Serono, Billerica, MA, USA.
W GuoClinical Oncology, Early Development, EMD Serono, Billerica, MA, USA.
B D SmithGlobal Biostatistics, Hematologic Cancer and BMT, Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAntineoplastic AgentsHematologic NeoplasmsHumansMiddle AgedNiacinamideYoung AdultAntineoplastic AgentsN-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamideNiacinamide

Identifiers

PMID26657199
PMCPMC4735070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.